The global head and neck cancer drugs market size is calculated at USD 1.90 billion in 2024, grew to USD 2.05 billion in 2025, and is predicted to hit around USD 4.06 billion by 2034, expanding at a CAGR of 7.88% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Head and Neck Cancer Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Head and Neck Cancer Drugs Market, by Treatment Type, 2024-2034
8.1.1. Targeted Therapy
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Chemotherapy
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Radiation Therapy
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Immunotherapy
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Head and Neck Cancer Drugs Market, by Sales Channel, 2024-2034
9.1.1. Retail Pharmacies
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Hospital Pharmacies
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Online Pharmacies
9.1.3.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.1.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.5.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Sales Channel (2021-2034)
11.1. AstraZeneca PLC
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Bristol-Myers Squibb Company
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Eli Lilly and Company
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Fortress Biotech, Inc
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. F. Hoffmann-La Roche Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Immutep Limited
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Merck & Co., Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Merck KGaA
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Novartis AG
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Pfizer Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample